<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643886</url>
  </required_header>
  <id_info>
    <org_study_id>GEM-CL-10302</org_study_id>
    <secondary_id>REGATTA</secondary_id>
    <nct_id>NCT04643886</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration</brief_title>
  <official_title>A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gemini Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gemini Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects&#xD;
      of repeat GEM103 IVT injections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, multi-center, open-label, multiple dose study in subjects with geographic&#xD;
      atrophy (GA) secondary to dry Age-related Macular Degeneration (dry AMD) to investigate the&#xD;
      safety, PK/PD, biomarker and early clinical effect of GEM103 repeat IVT injections.&#xD;
&#xD;
      Subjects will undergo clinical and ophthalmic assessments for determination of inclusion in&#xD;
      the study. Subjects who participated in the Phase 1 Study (GEM-CL-10301) as well as treatment&#xD;
      na√Øve subjects that did not participate in the GEM-CL-10301 Study and who meet all&#xD;
      eligibility criteria will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of intravitreal (IVT) injections of GEM103, as measured by number of subjects with ocular adverse events.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the clinical effect of GEM103 IVT injection, as the change from baseline in best corrected visual acuity (BCVA) scores as assessed by ETDRS scale.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the total CFH levels in aqueous humor after GEM103 IVT injection, whenever possible.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <condition>Geographic Atrophy</condition>
  <condition>Macular Degeneration</condition>
  <condition>Retinal Disease</condition>
  <condition>Retinal Degeneration</condition>
  <arm_group>
    <arm_group_label>Cohort with Genetic Profile A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have Genetic Profile A.&#xD;
Intervention: Biological: GEM103.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort with Genetic Profile B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have Genetic Profile B.&#xD;
Intervention: Biological: GEM103</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GEM103</intervention_name>
    <description>Biological</description>
    <arm_group_label>Cohort with Genetic Profile A</arm_group_label>
    <arm_group_label>Cohort with Genetic Profile B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 50 years old at the time of signed informed consent.&#xD;
&#xD;
          2. Must have one of the following genetic profiles:&#xD;
&#xD;
               1. Genetic Profile A.&#xD;
&#xD;
               2. Genetic Profile B.&#xD;
&#xD;
          3. BCVA in the study eye of 24 to 83 letters using ETDRS Chart Visual Acuity (VA) Scale&#xD;
             (approximately equivalent to Snellen VA of 20/25 to 20/320).&#xD;
&#xD;
          4. Confirmed diagnosis of GA in the study eye where total size of all GA lesions in the&#xD;
             study eye must be within 0.5 to 15.01- and 7- disc areas.&#xD;
&#xD;
          5. Sufficiently clear ocular media and able to cooperate with ophthalmic visual function&#xD;
             testing and anatomic assessment in the study eye.&#xD;
&#xD;
          6. Understands the full nature and purpose of the study and provides informed consent&#xD;
             prior to initiation of any study procedure; all subjects with a reproductive potential&#xD;
             must agree to use effective contraceptive methods through the end of study (EOS)&#xD;
             Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of the following ocular conditions - in the study eye:&#xD;
&#xD;
               1. Any history of exudative Age-related Macular Degeneration or choroidal&#xD;
                  neovascularization.&#xD;
&#xD;
               2. Any active ocular disease or condition that could confound the assessment of the&#xD;
                  macula or be a contraindication to IVT injection.&#xD;
&#xD;
               3. Any intraocular surgery, with the exception of stable intraocular lens&#xD;
                  replacement surgery more than 3 months prior to consent.&#xD;
&#xD;
               4. Aphakia or complete absence of the posterior capsule.&#xD;
&#xD;
               5. History of laser therapy to the macula or fundus or extensive laser to the&#xD;
                  retina.&#xD;
&#xD;
               6. Prior corneal transplant.&#xD;
&#xD;
          2. Presence of any of the following ocular conditions - in either eye:&#xD;
&#xD;
               1. History of herpetic infection.&#xD;
&#xD;
               2. Concurrent disease that could require medical or surgical intervention during the&#xD;
                  study period.&#xD;
&#xD;
               3. Active uveitis and/or vitritis (grade: trace or above).&#xD;
&#xD;
               4. History of idiopathic or autoimmune-associated uveitis.&#xD;
&#xD;
               5. Active blepharitis, conjunctivitis, keratitis, episcleritis, scleritis, or&#xD;
                  endophthalmitis.&#xD;
&#xD;
               6. Any ophthalmologic condition that reduces the clarity of the media and that, in&#xD;
                  the opinion of the Investigator, interferes with ophthalmologic examination.&#xD;
&#xD;
          3. In the opinion of the Investigator, the subject has any prior or ongoing medical&#xD;
             condition (e.g., ocular other than dry AMD, systemic, psychiatric) or clinically&#xD;
             significant screening laboratory value that may present a safety risk, interfere with&#xD;
             study compliance or study follow-up, or confound data interpretation throughout the&#xD;
             follow-up period.&#xD;
&#xD;
          4. Female subjects must not be pregnant or lactating, nor plan to become pregnant during&#xD;
             the study.&#xD;
&#xD;
          5. Current use of medications known to be toxic to the lens, retina, or optic nerve.&#xD;
&#xD;
          6. Use of any investigational new drug or other experimental treatment in the last 6&#xD;
             months, and/or receipt of any prior gene therapy (e.g., AAV) or ocular device&#xD;
             implantation (other than PCIOL placement following cataract surgery)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Associated Retina Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of San Diego</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Retina Associates</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Group of New England</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Care Specialists</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates of Florida</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Vitreoretinal Associates</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Retina PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates SC</name>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raj K Maturi MD PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Vision Research Foundation</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute, LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Center of New Jersey</name>
      <address>
        <city>Bloomfield</city>
        <state>New Jersey</state>
        <zip>07003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Carolina Retinal Associates</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose and Throat Associates PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Vision</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wagner Macula and Retina Center</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

